We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
eCFR and Guidances
Device Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
eCFR and Guidances
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
» Sandoz Launches Generic Cipralex in Europe
Sandoz Launches Generic Cipralex in Europe
June 17, 2014
Pharmaceuticals
Commercial Operations
Germany-based Sandoz has launched a version of Lundbeck’s antidepressant Cipralex in several European countries, the generic firm said.
To View This Article:
Login
Email
Password
Register
Remember Me
Forgot your password?
Subscribe To Generic Line
Buy This Article Now
Add this article to your cart for $40.00
Upcoming Events
19
Jan
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
21
Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26
Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27
Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27
Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09
Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
Featured Products
Biological Risk Evaluation and Management for Medical Devices
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
Featured Stories
U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail
Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance
Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy
Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
